The S&P/ASX 200 index (ASX: XJO) is home to 200 of the largest listed companies on the Australian share market.
Among these 200 companies are some true blue chip stars that could form the foundations for a winning portfolio.
But which ASX 200 shares should you consider buying right now? Two that have recently been named as buys are listed below:
CSL Limited (ASX: CSL)
The first ASX 200 share that analysts rate as a buy is CSL.
It is one of the world's leading biotherapeutics companies with a collection of industry-leading therapies. This includes therapies such as Privigen, Hizentra, Idelvion, and Afstyla.
But CSL is never one to rest on its laurels. As well as not being afraid to make major acquisitions, such as Vifor Pharma last year, the company reinvests in the region of 12% of its sales back into research and development (R&D) activities each year. This ensures that it has an R&D pipeline containing some potentially lucrative and life-saving therapies and vaccines.
Combined with its new plasma collection technology, the future looks bright for this ASX 200 blue chip star.
As a result, it will come as no surprise to learn that a large number of brokers are recommending CSL shares as a buy. One of those is Citi, which has a buy rating and $350 price target.
ResMed Inc. (ASX: RMD)
Another ASX 200 share that could be a great addition to your portfolio is ResMed.
If you're one of the estimated one in five people with a sleep disorder globally, you might be well aware of ResMed and its products. Though, that said, with the vast majority of sufferers still undiagnosed, perhaps you won't be.
However, with education around sleep disorders and the health risks they pose improving each year, ResMed looks well-placed to continue its solid growth long into the future. Particularly given its industry-leading products, R&D investment, and wide distribution network.
Goldman Sachs is bullish on ResMed. It currently has a buy rating and $38.00 price target on its shares.
